Product News
Filter News
Found 183,870 articles
-
Under the terms of the deal, Roivant is paying iNtRON Bio $10 million upfront. iNtRON will be eligible for milestone payments. When the first patient receives treatment in a U.S. Phase II clinical trial scheduled for 2019, the first milestone will be $30 million.
-
Germany’s pharma giant Merck KGaA and Silicon Valley data analytics company Palantir Technologies are forming a joint venture called Syntropy. Syntropy will be based in Boston and will focus on cancer data analytics tools.
-
Seqirus, a wholly owned subsidiary of CSL, is expanding its manufacturing plant in North Carolina. It expects to invest $140 million in the expansion.
-
Less than a week after Boston Scientific announced that it was undergoing a restructuring that could result in some job losses, the company announced that it will acquire U.K.-based BTG plc., a surgical device manufacturer for about $4.2 billion.
-
Quest Products Announces New ProVent® Hemp Patch and ProVent® Wart Remover Products
11/20/2018
Hemp Patch designed for pain relief and a Wart Remover that includes natural botanicals.
-
GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles
11/20/2018
First of their kind, myrcene nanoparticles are central to a novel, time-released therapeutic for neuropathic pain
-
DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting
11/20/2018
DelMar Pharmaceuticals, Inc. presented scientific updates, including data from two ongoing clinical trials, at the 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) held on November 15-18, 2018 in New Orleans, LA.
-
MEDICREA® Achieves 3,000 Surgery Milestone with UNiD ASI™ and Patient Specific Implants
11/20/2018
This Press Release includes hyperlinks. Click the blue words to access extra content including videos and abstracts.
-
NAMSA Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
11/20/2018
Newly-developed website to serve as a resource for Asia-Pacific (APAC) medical device sponsors.
-
Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035
11/20/2018
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations.
-
E-Motion Medical Receives CE Mark Approval for Its Novel Stimulation Therapy for Patients With Acute Digestive Dysmotility
11/20/2018
E-Motion Medical Ltd. announced today it has received CE Mark approval for its lead product, the E-Motion System™, providing stimulation therapy that restores the natural motor function of the digestive system for patients with acute gastrointestinal dysmotility (GID).
-
Body and Mind Inc. Reports Premium Flower Test Over 30% THC
11/20/2018
Body and Mind Inc. (CSE: BAMM) (US OTC: BMMJ) (the "Company" or "BaM") is pleased to report record testing results from the most recent harvest in Nevada.
-
Innovative Smartphone-based Retinal Camera Outperforms Expensive Table-top System in Detecting Diabetic Retinopathy in a Two-year Study
11/20/2018
At one-fifth the cost, Remidio Fundus-on-Phone (FOP) promises dramatic public health impact in preventing blindness by enabling early detection of diabetic retinopathy
-
EpicGenetics Announces 50 Percent Increase in Fibromyalgia FM/a® Test Requests Since September
11/20/2018
EpicGenetics, the biomedical company that developed and offers the FM/a Test, the FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia, today announced a 50 percent growth in applications for the test.
-
Livongo Achieves Full CDC Recognition for Diabetes Prevention Program
11/20/2018
Full Recognition Demonstrates Program Effectiveness in Preventing Type 2 Diabetes
-
Philips launches IntelliSpace Discovery* Research platform at RSNA to support the development and deployment of Artificial Intelligence assets in radiology
11/20/2018
Powered by Philips HealthSuite, open platform offers radiologists comprehensive data analytics in medical imaging
-
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
11/20/2018
Ipsen and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227).
-
Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint
11/20/2018
The study achieved its primary efficacy endpoint (p<0.0001)
-
An ovarian cancer treatment co-developed by Germany’s Merck KGaA and Pfizer failed to meet endpoints for overall survival and progression-free survival in a Phase III trial.
-
The UK’s exit from the European Union, Brexit, will impact numerous industries in the UK and Europe, but the biopharma industry has its own unique challenges.